STERIS plc (Ireland) Ordinary Shares (STE): Price and Financial Metrics
STERIS plc (Ireland) Ordinary Shares (STE)
Today's Latest Price: $184.96 USD
Updated Oct 27 1:20pm
Add STE to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
STE Stock Summary
- STERIS plc's market capitalization of $15,855,599,461 is ahead of 88.72% of US-listed equities.
- The price/operating cash flow metric for STERIS plc is higher than 84.1% of stocks in our set with a positive cash flow.
- The volatility of STERIS plc's share price is greater than that of merely 6.81% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to STERIS plc, a group of peers worth examining would be SNN, COO, PNR, BRO, and CSL.
- Visit STE's SEC page to see the company's official filings. To visit the company's web site, go to www.steris.com.
STE Stock Price Chart Interactive Chart >
STE Price/Volume Stats
| Current price | $184.96 | 52-week high | $192.97 |
| Prev. close | $186.42 | 52-week low | $105.69 |
| Day low | $184.84 | Volume | 96,673 |
| Day high | $188.01 | Avg. volume | 590,835 |
| 50-day MA | $171.59 | Dividend yield | 0.86% |
| 200-day MA | $157.02 | Market Cap | 15.73B |
STERIS plc (Ireland) Ordinary Shares (STE) Company Bio
Steris Corporation develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and procedural support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The company was founded in 1985 and is based in Mentor, Ohio.
STE Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $184.96 | $134.5 | -28% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for STERIS plc. To summarize, we found that STERIS plc ranked in the 39th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 27.5%. In terms of the factors that were most noteworthy in this DCF analysis for STE, they are:
- The company's debt burden, as measured by earnings divided by interest payments, is 13.87; that's higher than 77.47% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than just 18.27% of the free cash flow producing stocks we're observing.
- STE's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 40.92% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -29% |
| 1% | -29% |
| 2% | -28% |
| 3% | -27% |
| 4% | -26% |
| 5% | -26% |
ICLR, EBS, CNC, PAHC, and BDX can be thought of as valuation peers to STE, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...